Table 1.
Initial characteristics and therapy of the 75 PCNSL study patients
| Variable | Patients |
|---|---|
| Patients, n | 75 |
| Sex | |
| Female | 29 (39) |
| Male | 46 (61) |
| Age, y | |
| Median (range) | 12.5 (1.25-18.87) |
| <10 | 26 (35) |
| ≥10 to <15 | 31 (41) |
| ≥15 | 18 (24) |
| Preexisting disorder | |
| Yes | 14 (19) |
| No | 56 (75) |
| Unknown | 5 (6) |
| Lansky score | |
| <40% | 14 (19) |
| ≥40-79% | 27 (36) |
| ≥80% | 19 (25) |
| Unknown/not applicable | 15 (20) |
| B symptoms | |
| Yes | 9 (12) |
| No | 59 (79) |
| Unknown | 7 (9) |
| Cranial nerve palsies | |
| Yes | 33 (44) |
| No | 39 (52) |
| Unknown | 3 (4) |
| Histopathologic subtype | |
| DLBCL | 37 (49) |
| Burkitt lymphoma | 9 (12) |
| Mature B-NHL NOS | 5 (7) |
| ALCL | 17 (23) |
| Other NHL | 7 (9) |
| BCP LBL, n | 4 |
| EN MZL, n | 1 |
| PTCL, n | 2 |
| Localization | |
| Intracranial | 70 (93) |
| Intraspinal only | 2 (3) |
| Leptomeningeal only | 3 (4) |
| No. of lesions | |
| 1 | 36 (48) |
| ≥2 | 32 (43) |
| Unknown/not applicable | 7 (9) |
| Initial LDH level, U/L | |
| <500 | 53 (71) |
| ≥500 | 10 (13) |
| Unknown | 12 (16) |
| Initial therapy | |
| Chemo only | 31 (41) |
| Chemo and rituximab | 15 (20) |
| Chemo and RT | 24 (32) |
| Chemo and rituximab and RT | 2 (3) |
| Other | 3 (4) |
| Therapy | |
| Pediatric NHL-type* | 57 (76) |
| Adult NHL-type† | 1 (1) |
| Miscellaneous‡ | 17 (23) |
| Chemotherapeutic drugs, n§ | |
| High-dose methotrexate | 68 |
| High-dose cytarabine | 55 |
| Anthracyclines | 59 |
| Alkylating agents | 64 |
| Intrathecal therapies | 69 |
| RT | |
| Yes | 26 (35) |
| No | 49 (65) |
| Stem cell therapy in CR1 | |
| Autologous | 3 (4) |
| Allogeneic | 1 (1) |
| Rituximab in mature B-NHL | 17 (32) |
Unless otherwise noted, data are shown as n (%).
BCP, B-cell precursor; Chemo, chemotherapy; CR1, first complete remission; EN MZL, extranodal marginal zone lymphoma; LDH, lactate dehydrogenase; NOS, not otherwise specified; RT, radiotherapy.
NHL Berlin-Frankfurt-Münster therapy, n = 30; Lymphomes Malins B therapy, n = 14; Inter–B-NHL therapy, n = 5; Associazione Italiana Ematologia Oncologia Pediatrica linfoma non-Hodgkin (AIEOP LNH) therapy, n = 2; EICNHL therapy, n = 2; Sociedade de Hematologia e Oncologia Pediatrica LNH therapy, n = 1; Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL therapy, n = 2;, Children's Oncology Group AALL1131 trial, n = 1, including 17 of the 26 (65%) patients with RT.
Cancer and Leukemia Group B 50202 trial, n = 1.
Including 9 of the 26 (35%) patients with RT.
High-dose-methotrexate (n = 68): <5 g/m2, n = 5; 5 g/m2, n = 38; 8 g/m2, n = 25. High-dose-cytarabine (n = 55): ≤6 g/m2, n = 13; 8 g/m2, n = 1; 12 to 12.5 g/m2, n = 41. Anthracyclines (n = 59) with doxorubicin in 57 patients and a median cumulative dose of 100 mg/m2 (range: 25-240 mg/m2).